Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD4 | Q53EL6 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | DNTT | P04053 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673923 | 1.00 | PDCD4 (0.43) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL3663425 | 1.00 | PDCD4 (0.43) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL2315807 | 1.00 | PDCD4 (0.43) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL1895638 | 1.00 | PDCD4 (0.43) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL3505080 | 0.98 | PDCD4 (0.40) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL9993726 | 0.92 | PDCD4 (0.38) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL30503116 | 0.88 | DNTT (0.39) | PDCD4CYP1A2DNTTPPARGCES2 | |
| SCHEMBL9991171 | 0.81 | PDCD4 (0.37) | PDCD4 | |
| SCHEMBL16431359 | 0.80 | PDCD4 (0.38) | PDCD4CYP1A2CES2 | |
| SCHEMBL9995097 | 0.80 | PAOX (0.36) | PDCD4DNTTPPARGNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5541221-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0637240-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES FOR INHIBITING BONE LOSS | ALLERGAN, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5387606-A | Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss | ALLERGAN, INC. (US) | 1995-02-07 | — | — | US | disclosed |
| US-5268387-A | Containing ester or carbamate group | ALLERGAN, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| WO-1993021915-A1 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING BONE LOSS CONTAINING 3 AND 4-SUBSTITUTED 2(5H)-FURANONES | ALLERGAN, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0524979-A4 | 2(5H)-FURANONES SUBSTITUTED IN THE 5 AND OR IN THE 4 POSITION, AS ANTI-INFLAMMATORY AGENTS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0524979-A1 | 2(5H)-FURANONES SUBSTITUTED IN THE 5 AND OR IN THE 4 POSITION, AS ANTI-INFLAMMATORY AGENTS | ALLERGAN, INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016055-A1 | 2(5H)-FURANONES SUBSTITUTED IN THE 5 AND OR IN THE 4 POSITION, AS ANTI-INFLAMMATORY AGENTS | ALLERGAN, INC. (US) | 1991-10-31 | — | — | WO | disclosed |